Atypical Teratoid/Rhabdoid Tumor (ATRT)

Status: draft · Last updated 2026-11-13 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Biology: SMARCB1 (INI1) loss, rarely SMARCA4. Loss of INI1 staining on IHC is the diagnostic key .
  • Three subgroups :
    • TYR: infratentorial; youngest.
    • SHH: supra- or infratentorial; spans both.
    • MYC: supratentorial or spinal; oldest; edema.
  • Germline SMARCB1 in about a quarter to a third :
    • Prognosis: worse; 2-year OS 7%.
    • Inheritance: usually de novo or mosaic.
    • Always do germline testing and offer counseling.
  • Risk :
    • Age under 1 with non-TYR: 5-year OS 0%.
    • Age 1 or older with TYR: about 72%.
    • Metastatic infants do worst.
  • Treatment :
    • Approach: maximal safe surgery, intensive chemotherapy (often high-dose with stem cell rescue), and radiotherapy (focal in young children, CSI in older).
    • ACNS0333: 4-year OS 43%.
    • Extent of resection: its independent value is uncertain.

Landmark papers

  • COG ACNS0333 (Reddy et al., J Clin Oncol 2020): 2 induction cycles, 3 cycles of high-dose chemotherapy with stem cell rescue, and involved-field (3D conformal) radiation. 4-year EFS was 37% and OS 43% .

ATRT is an embryonal, CNS WHO grade 4 tumor and one of the most common malignant brain tumors in infants . Its defining genetic event is biallelic inactivation of SMARCB1 (INI1), or rarely of SMARCA4 . Apart from that, the genome is strikingly quiet.

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:atrt_subgroups:8f588eda8ce00aff© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Midsagittal infant brain showing where the three consensus atypical teratoid/rhabdoid tumour subgroups arise: ATRT-TYR in the posterior fossa, ATRT-SHH straddling the tentorium and in the hemisphere, and ATRT-MYC in the hemisphere with peritumoral edema and in the spinal cord; all lose SMARCB1 (INI1), rarely SMARCA4ATRT CONSENSUS SUBGROUPS (MIDSAGITTAL INFANT BRAIN, ANTERIOR LEFT)ATRT-MYCsupratentorial and spinal; oldest(median 27 mo); edemaATRT-MYC, spinalATRT-SHHsupra- or infratentorial; onlygroup spanning bothATRT-TYRmostly infratentorial (75%);youngest (median 12 mo)All: SMARCB1 (INI1) loss; rarely SMARCA4bulky, heterogeneous masses with cystic(pale) and hemorrhagic (dark) focischematic; not to scale
The three consensus ATRT molecular subgroups, midsagittal infant brain. ATRT-TYR: mostly infratentorial; youngest patients. ATRT-SHH: supratentorial or infratentorial, and the only group with tumors spanning both. ATRT-MYC: supratentorial and spinal, in the oldest patients, with marked peritumoral edema. All have SMARCB1 (INI1) loss, or rarely SMARCA4. Not to scale.

Biology and molecular subgroups

Germline predisposition (rhabdoid tumor predisposition syndrome)

Prognostic factors

Surgery

Adjuvant therapy

Related topics

References

  1. Johann PD, Erkek S, Zapatka M, et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 2016;29(3):379–393. doi:10.1016/j.ccell.2016.02.001. PMID 26923874. verified
  2. Ho B, Johann PD, Grabovska Y, et al. Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus. Neuro Oncol 2020;22(5):613–624. doi:10.1093/neuonc/noz235. PMID 31889194. verified
  3. Holdhof D, Johann PD, Spohn M, et al. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathol 2021;141(2):291–301. doi:10.1007/s00401-020-02250-7. PMID 33331994. verified
  4. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 2009;27(3):385–389. doi:10.1200/JCO.2008.18.7724. PMID 19064966. verified
  5. Reddy AT, Strother DR, Judkins AR, et al. Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: a report from the Children's Oncology Group trial ACNS0333. J Clin Oncol 2020;38(11):1175–1185. doi:10.1200/JCO.19.01776. PMID 32105509. verified
  6. Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Relevance of molecular groups in children with newly diagnosed atypical teratoid rhabdoid tumor: results from prospective St. Jude multi-institutional trials. Clin Cancer Res 2021;27(10):2879–2889. doi:10.1158/1078-0432.CCR-20-4731. PMID 33737307. verified
  7. Frühwald MC, Hasselblatt M, Nemes K, et al. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro Oncol 2020;22(7):1006–1017. doi:10.1093/neuonc/noz244. PMID 31883020. verified
  8. Torchia J, Picard D, Lafay-Cousin L, et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol 2015;16(5):569–582. doi:10.1016/S1470-2045(15)70114-270114-2). PMID 25882982. verified
  9. Bourdeaut F, Lequin D, Brugières L, et al. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res 2011;17(1):31–38. doi:10.1158/1078-0432.CCR-10-1795. PMID 21208904. verified
  10. Lafay-Cousin L, Hawkins C, Carret AS, et al. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer 2012;48(3):353–359. doi:10.1016/j.ejca.2011.09.005. PMID 22023887. verified
  11. Schrey D, Carceller Lechón F, Malietzis G, et al. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. J Neurooncol 2016;126(1):81–90. doi:10.1007/s11060-015-1904-0. PMID 26608522. verified
  12. Gupta NK, Godbole N, Sanmugananthan P, et al. Management of atypical teratoid/rhabdoid tumors in the pediatric population: a systematic review and meta-analysis. World Neurosurg 2024;181:e504–e515. doi:10.1016/j.wneu.2023.10.089. PMID 37871692. verified

Verification (2026-11-13):

Caveats: